Ignite Creation Date:
2025-12-24 @ 6:48 PM
Ignite Modification Date:
2025-12-31 @ 1:21 AM
Study NCT ID:
NCT01639157
Status:
COMPLETED
Last Update Posted:
2016-02-19
First Post:
2012-07-10
Is NOT Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
Impact of Buspirone Maintenance on the Reinforcing Effects of Cocaine
Sponsor:
Organization:
Raw JSON
{'hasResults': True, 'derivedSection': {'miscInfoModule': {'versionHolder': '2025-12-24'}, 'interventionBrowseModule': {'meshes': [{'id': 'D002065', 'term': 'Buspirone'}], 'ancestors': [{'id': 'D013141', 'term': 'Spiro Compounds'}, {'id': 'D006844', 'term': 'Hydrocarbons, Cyclic'}, {'id': 'D006838', 'term': 'Hydrocarbons'}, {'id': 'D009930', 'term': 'Organic Chemicals'}, {'id': 'D010879', 'term': 'Piperazines'}, {'id': 'D006573', 'term': 'Heterocyclic Compounds, 1-Ring'}, {'id': 'D006571', 'term': 'Heterocyclic Compounds'}, {'id': 'D011743', 'term': 'Pyrimidines'}, {'id': 'D011083', 'term': 'Polycyclic Compounds'}]}}, 'resultsSection': {'moreInfoModule': {'pointOfContact': {'email': 'william.stoops@uky.edu', 'phone': '859-257-5388', 'title': 'William W. Stoops, Ph.D.', 'organization': 'University of Kentucky'}, 'certainAgreement': {'piSponsorEmployee': False, 'restrictiveAgreement': False}}, 'adverseEventsModule': {'eventGroups': [{'id': 'EG000', 'title': 'Buspirone', 'description': 'Subjects will be maintained on buspirone.\n\nBuspirone: Subjects will be maintained on oral buspirone (administered 3 times daily) or placebo for 6 days each during the study in random order. These subjects will be the same as those who are maintained on placebo (i.e., the study uses a within-subjects design).', 'otherNumAtRisk': 9, 'otherNumAffected': 0, 'seriousNumAtRisk': 9, 'seriousNumAffected': 0}, {'id': 'EG001', 'title': 'Placebo', 'description': 'Subjects will be maintained on placebo.\n\nBuspirone: Subjects will be maintained on oral buspirone (administered 3 times daily) or placebo for 6 days each during the study in random order.These subjects will be the same as those who are maintained on buspirone (i.e., the study uses a within-subjects design).', 'otherNumAtRisk': 9, 'otherNumAffected': 0, 'seriousNumAtRisk': 9, 'seriousNumAffected': 0}], 'frequencyThreshold': '0'}, 'outcomeMeasuresModule': {'outcomeMeasures': [{'type': 'PRIMARY', 'title': 'Number of Times Cocaine Was Selected in the Presence of a Monetary Reward Alternative', 'denoms': [{'units': 'Participants', 'counts': [{'value': '9', 'groupId': 'OG000'}, {'value': '9', 'groupId': 'OG001'}]}], 'groups': [{'id': 'OG000', 'title': 'Buspirone', 'description': 'Subjects were maintained on 30 mg buspirone daily for 6 days.'}, {'id': 'OG001', 'title': 'Placebo', 'description': 'Subjects were maintained on placebo daily for 6 days.'}], 'classes': [{'title': '0 mg Cocaine', 'categories': [{'measurements': [{'value': '1.00', 'spread': '0.707', 'groupId': 'OG000'}, {'value': '1.22', 'spread': '0.813', 'groupId': 'OG001'}]}]}, {'title': '15 mg Cocaine', 'categories': [{'measurements': [{'value': '5.56', 'spread': '0.338', 'groupId': 'OG000'}, {'value': '5.33', 'spread': '0.441', 'groupId': 'OG001'}]}]}, {'title': '45 mg Cocaine', 'categories': [{'measurements': [{'value': '5', 'spread': '.289', 'groupId': 'OG000'}, {'value': '4.89', 'spread': '.455', 'groupId': 'OG001'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'One test per cocaine dose level per intervention for each participant over his/her 2 week inpatient admission', 'description': 'The reinforcing effects of cocaine were determined using a modified progressive ratio procedure (Stoops et al., 2010) in which subjects made 6 choices between available each available cocaine dose and money (US$0.25). Reinforcing effects are measured for each cocaine dose during both buspirone and placebo maintenance.', 'unitOfMeasure': 'Number of Cocaine Choices', 'dispersionType': 'Standard Error', 'reportingStatus': 'POSTED'}, {'type': 'SECONDARY', 'title': 'Peak Score on Sedative Subscale of the Adjective Rating Scale', 'denoms': [{'units': 'Participants', 'counts': [{'value': '9', 'groupId': 'OG000'}, {'value': '9', 'groupId': 'OG001'}]}], 'groups': [{'id': 'OG000', 'title': 'Buspirone', 'description': 'Subjects were maintained on 30 mg buspirone daily for 6 days.'}, {'id': 'OG001', 'title': 'Placebo', 'description': 'Subjects were maintained on placebo daily for 6 days.'}], 'classes': [{'title': '0 mg Cocaine', 'categories': [{'measurements': [{'value': '2.9', 'spread': '1.3', 'groupId': 'OG000'}, {'value': '3.6', 'spread': '1.6', 'groupId': 'OG001'}]}]}, {'title': '15 mg Cocaine', 'categories': [{'measurements': [{'value': '4.4', 'spread': '1.7', 'groupId': 'OG000'}, {'value': '4.8', 'spread': '1.8', 'groupId': 'OG001'}]}]}, {'title': '45 mg Cocaine', 'categories': [{'measurements': [{'value': '5.6', 'spread': '1.8', 'groupId': 'OG000'}, {'value': '3.1', 'spread': '1.1', 'groupId': 'OG001'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Subjects completed this measure at 15 minute intervals for 45 minutes after sampling each cocaine dose under both buspirone and placebo maintenance conditions.', 'description': 'Subjects completed 16 items that loaded into the Sedative Subscale of the Adjective Rating Scale. The items were rated 0-4 on a Likert-type scale and the sum for the 16 "sedative" items was summed to yield the Sedative Subscale score. The maximum score for this scale was 64, the minimum was 0. Higher values represent greater subjective effects on this item. Peak scores were calculated from multiple assessments for each cocaine dose under both buspirone and placebo conditions.', 'unitOfMeasure': 'arbitrary units on a Likert-type scale', 'dispersionType': 'Standard Error', 'reportingStatus': 'POSTED'}, {'type': 'SECONDARY', 'title': 'Peak Systolic Blood Pressure', 'denoms': [{'units': 'Participants', 'counts': [{'value': '9', 'groupId': 'OG000'}, {'value': '9', 'groupId': 'OG001'}]}], 'groups': [{'id': 'OG000', 'title': 'Buspirone', 'description': 'Subjects were maintained on 30 mg buspirone daily for 6 days.'}, {'id': 'OG001', 'title': 'Placebo', 'description': 'Subjects were maintained on placebo daily for 6 days.'}], 'classes': [{'title': '0 mg Cocaine', 'categories': [{'measurements': [{'value': '120.8', 'spread': '3.3', 'groupId': 'OG000'}, {'value': '120.6', 'spread': '3.2', 'groupId': 'OG001'}]}]}, {'title': '15 mg Cocaine', 'categories': [{'measurements': [{'value': '128.7', 'spread': '1.3', 'groupId': 'OG000'}, {'value': '127.0', 'spread': '3.4', 'groupId': 'OG001'}]}]}, {'title': '45 mg Cocaine', 'categories': [{'measurements': [{'value': '127.1', 'spread': '2.9', 'groupId': 'OG000'}, {'value': '131.8', 'spread': '3.0', 'groupId': 'OG001'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'This measure was completed at 15 minute intervals for 45 minutes after sampling each cocaine dose under both buspirone and placebo maintenance conditions.', 'description': 'Systolic blood pressure was measured with an automated monitor. Higher values represent greater systolic pressure. Peak scores were calculated from multiple assessments for each cocaine dose under both buspirone and placebo conditions.', 'unitOfMeasure': 'mmHg', 'dispersionType': 'Standard Error', 'reportingStatus': 'POSTED'}, {'type': 'SECONDARY', 'title': 'Peak Score on Stimulant Subscale of the Adjective Rating Scale', 'denoms': [{'units': 'Participants', 'counts': [{'value': '9', 'groupId': 'OG000'}, {'value': '9', 'groupId': 'OG001'}]}], 'groups': [{'id': 'OG000', 'title': 'Buspirone', 'description': 'Subjects were maintained on 30 mg buspirone daily for 6 days.'}, {'id': 'OG001', 'title': 'Placebo', 'description': 'Subjects were maintained on placebo daily for 6 days.'}], 'classes': [{'title': '0 mg Cocaine', 'categories': [{'measurements': [{'value': '5', 'spread': '1.7', 'groupId': 'OG000'}, {'value': '4.4', 'spread': '1.1', 'groupId': 'OG001'}]}]}, {'title': '15 mg Cocaine', 'categories': [{'measurements': [{'value': '9.8', 'spread': '1.7', 'groupId': 'OG000'}, {'value': '9', 'spread': '1.5', 'groupId': 'OG001'}]}]}, {'title': '45 mg Cocaine', 'categories': [{'measurements': [{'value': '11.4', 'spread': '2.1', 'groupId': 'OG000'}, {'value': '11.3', 'spread': '2.0', 'groupId': 'OG001'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Subjects completed this measure at 15 minute intervals for 45 minutes after sampling each cocaine dose under both buspirone and placebo maintenance conditions.', 'description': 'Subjects completed 16 items that loaded into the Stimulant Subscale of the Adjective Rating Scale. The items were rated 0-4 on a Likert-type scale and the sum for the 16 "sedative" items was summed to yield the Stimulant Subscale score. The maximum score for this scale was 64, the minimum was 0. Higher values represent greater subjective effects on this item. Peak scores were calculated from multiple assessments for each cocaine dose under both buspirone and placebo conditions.', 'unitOfMeasure': 'arbitrary units on a Likert-type scale', 'dispersionType': 'Standard Error', 'reportingStatus': 'POSTED'}, {'type': 'SECONDARY', 'title': 'Peak Ratings of "Active, Alert, Energetic" on the Visual Analog Scale', 'denoms': [{'units': 'Participants', 'counts': [{'value': '9', 'groupId': 'OG000'}, {'value': '9', 'groupId': 'OG001'}]}], 'groups': [{'id': 'OG000', 'title': 'Buspirone', 'description': 'Subjects were maintained on 30 mg buspirone daily for 6 days.'}, {'id': 'OG001', 'title': 'Placebo', 'description': 'Subjects were maintained on placebo daily for 6 days.'}], 'classes': [{'title': '0 mg Cocaine', 'categories': [{'measurements': [{'value': '3.8', 'spread': '3.0', 'groupId': 'OG000'}, {'value': '3.7', 'spread': '2.9', 'groupId': 'OG001'}]}]}, {'title': '15 mg Cocaine', 'categories': [{'measurements': [{'value': '20.1', 'spread': '6.0', 'groupId': 'OG000'}, {'value': '17.4', 'spread': '5.4', 'groupId': 'OG001'}]}]}, {'title': '45 mg Cocaine', 'categories': [{'measurements': [{'value': '24.7', 'spread': '7.7', 'groupId': 'OG000'}, {'value': '33.3', 'spread': '8.3', 'groupId': 'OG001'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Subjects completed this measure at 15 minute intervals for 45 minutes after sampling each cocaine dose under both buspirone and placebo maintenance conditions.', 'description': 'Subjects rated their feelings of "Active, Alert, Energetic" on a Visual Analog Scale. This item was rated from 0 (minimum)-100 (maximum) on a Visual Analog Scale. Higher values represent greater subjective effects on this item. Peak scores were calculated from multiple assessments for each cocaine dose under both buspirone and placebo conditions.', 'unitOfMeasure': 'arbitary units on a Visual Analog Scale', 'dispersionType': 'Standard Error', 'reportingStatus': 'POSTED'}, {'type': 'SECONDARY', 'title': 'Peak Ratings of "Any Effect" on the Visual Analog Scale', 'denoms': [{'units': 'Participants', 'counts': [{'value': '9', 'groupId': 'OG000'}, {'value': '9', 'groupId': 'OG001'}]}], 'groups': [{'id': 'OG000', 'title': 'Buspirone', 'description': 'Subjects were maintained on 30 mg buspirone daily for 6 days.'}, {'id': 'OG001', 'title': 'Placebo', 'description': 'Subjects were maintained on placebo daily for 6 days.'}], 'classes': [{'title': '0 mg Cocaine', 'categories': [{'measurements': [{'value': '6.2', 'spread': '4.8', 'groupId': 'OG000'}, {'value': '6.1', 'spread': '3.7', 'groupId': 'OG001'}]}]}, {'title': '15 mg Cocaine', 'categories': [{'measurements': [{'value': '23.0', 'spread': '4.7', 'groupId': 'OG000'}, {'value': '17.3', 'spread': '5.2', 'groupId': 'OG001'}]}]}, {'title': '45 mg Cocaine', 'categories': [{'measurements': [{'value': '26', 'spread': '6.5', 'groupId': 'OG000'}, {'value': '33.4', 'spread': '8.0', 'groupId': 'OG001'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Subjects completed this measure at 15 minute intervals for 45 minutes after sampling each cocaine dose under both buspirone and placebo maintenance conditions.', 'description': 'Subjects rated their feelings of "Any Effect" on a Visual Analog Scale. This item was rated from 0 (minimum)-100 (maximum) on a Visual Analog Scale. Higher values represent greater subjective effects on this item. Peak scores were calculated from multiple assessments for each cocaine dose under both buspirone and placebo conditions.', 'unitOfMeasure': 'arbitary units on a Visual Analog Scale', 'dispersionType': 'Standard Error', 'reportingStatus': 'POSTED'}, {'type': 'SECONDARY', 'title': 'Peak Ratings of "Bad Effects" on the Visual Analog Scale', 'denoms': [{'units': 'Participants', 'counts': [{'value': '9', 'groupId': 'OG000'}, {'value': '9', 'groupId': 'OG001'}]}], 'groups': [{'id': 'OG000', 'title': 'Buspirone', 'description': 'Subjects were maintained on 30 mg buspirone daily for 6 days.'}, {'id': 'OG001', 'title': 'Placebo', 'description': 'Subjects were maintained on placebo daily for 6 days.'}], 'classes': [{'title': '0 mg Cocaine', 'categories': [{'measurements': [{'value': '4.3', 'spread': '3.5', 'groupId': 'OG000'}, {'value': '5.9', 'spread': '3.8', 'groupId': 'OG001'}]}]}, {'title': '15 mg Cocaine', 'categories': [{'measurements': [{'value': '6.7', 'spread': '3.0', 'groupId': 'OG000'}, {'value': '7.7', 'spread': '2.9', 'groupId': 'OG001'}]}]}, {'title': '45 mg Cocaine', 'categories': [{'measurements': [{'value': '12.2', 'spread': '4.8', 'groupId': 'OG000'}, {'value': '9.1', 'spread': '4.4', 'groupId': 'OG001'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Subjects completed this measure at 15 minute intervals for 45 minutes after sampling each cocaine dose under both buspirone and placebo maintenance conditions.', 'description': 'Subjects rated their feelings of "Bad Effects" on a Visual Analog Scale. This item was rated from 0 (minimum)-100 (maximum) on a Visual Analog Scale. Higher values represent greater subjective effects on this item. Peak scores were calculated from multiple assessments for each cocaine dose under both buspirone and placebo conditions.', 'unitOfMeasure': 'arbitary units on a Visual Analog Scale', 'dispersionType': 'Standard Error', 'reportingStatus': 'POSTED'}, {'type': 'SECONDARY', 'title': 'Peak Ratings of "Euphoric" on the Visual Analog Scale', 'denoms': [{'units': 'Participants', 'counts': [{'value': '9', 'groupId': 'OG000'}, {'value': '9', 'groupId': 'OG001'}]}], 'groups': [{'id': 'OG000', 'title': 'Buspirone', 'description': 'Subjects were maintained on 30 mg buspirone daily for 6 days.'}, {'id': 'OG001', 'title': 'Placebo', 'description': 'Subjects were maintained on placebo daily for 6 days.'}], 'classes': [{'title': '0 mg Cocaine', 'categories': [{'measurements': [{'value': '5.6', 'spread': '4.7', 'groupId': 'OG000'}, {'value': '5.9', 'spread': '4.9', 'groupId': 'OG001'}]}]}, {'title': '15 mg Cocaine', 'categories': [{'measurements': [{'value': '15.8', 'spread': '8.2', 'groupId': 'OG000'}, {'value': '13.1', 'spread': '7.4', 'groupId': 'OG001'}]}]}, {'title': '45 mg Cocaine', 'categories': [{'measurements': [{'value': '16.4', 'spread': '9.3', 'groupId': 'OG000'}, {'value': '14.1', 'spread': '6.9', 'groupId': 'OG001'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Subjects completed this measure at 15 minute intervals for 45 minutes after sampling each cocaine dose under both buspirone and placebo maintenance conditions.', 'description': 'Subjects rated their feelings of "Euphoric" on a Visual Analog Scale. This item was rated from 0 (minimum)-100 (maximum) on a Visual Analog Scale. Higher values represent greater subjective effects on this item. Peak scores were calculated from multiple assessments for each cocaine dose under both buspirone and placebo conditions.', 'unitOfMeasure': 'arbitary units on a Visual Analog Scale', 'dispersionType': 'Standard Error', 'reportingStatus': 'POSTED'}, {'type': 'SECONDARY', 'title': 'Peak Ratings of "Good Effects" on the Visual Analog Scale', 'denoms': [{'units': 'Participants', 'counts': [{'value': '9', 'groupId': 'OG000'}, {'value': '9', 'groupId': 'OG001'}]}], 'groups': [{'id': 'OG000', 'title': 'Buspirone', 'description': 'Subjects were maintained on 30 mg buspirone daily for 6 days.'}, {'id': 'OG001', 'title': 'Placebo', 'description': 'Subjects were maintained on placebo daily for 6 days.'}], 'classes': [{'title': '0 mg Cocaine', 'categories': [{'measurements': [{'value': '4.8', 'spread': '3.9', 'groupId': 'OG000'}, {'value': '3.3', 'spread': '2.6', 'groupId': 'OG001'}]}]}, {'title': '15 mg Cocaine', 'categories': [{'measurements': [{'value': '21.3', 'spread': '4.9', 'groupId': 'OG000'}, {'value': '15.7', 'spread': '5.0', 'groupId': 'OG001'}]}]}, {'title': '45 mg Cocaine', 'categories': [{'measurements': [{'value': '21.2', 'spread': '6.1', 'groupId': 'OG000'}, {'value': '32.3', 'spread': '6.8', 'groupId': 'OG001'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Subjects completed this measure at 15 minute intervals for 45 minutes after sampling each cocaine dose under both buspirone and placebo maintenance conditions.', 'description': 'Subjects rated their feelings of "Good Effects" on a Visual Analog Scale. This item was rated from 0 (minimum)-100 (maximum) on a Visual Analog Scale. Higher values represent greater subjective effects on this item. Peak scores were calculated from multiple assessments for each cocaine dose under both buspirone and placebo conditions.', 'unitOfMeasure': 'arbitary units on a Visual Analog Scale', 'dispersionType': 'Standard Error', 'reportingStatus': 'POSTED'}, {'type': 'SECONDARY', 'title': 'Peak Ratings of "High" on the Visual Analog Scale', 'denoms': [{'units': 'Participants', 'counts': [{'value': '9', 'groupId': 'OG000'}, {'value': '9', 'groupId': 'OG001'}]}], 'groups': [{'id': 'OG000', 'title': 'Buspirone', 'description': 'Subjects were maintained on 30 mg buspirone daily for 6 days.'}, {'id': 'OG001', 'title': 'Placebo', 'description': 'Subjects were maintained on placebo daily for 6 days.'}], 'classes': [{'title': '0 mg Cocaine', 'categories': [{'measurements': [{'value': '5.1', 'spread': '4.4', 'groupId': 'OG000'}, {'value': '3.9', 'spread': '3.4', 'groupId': 'OG001'}]}]}, {'title': '15 mg Cocaine', 'categories': [{'measurements': [{'value': '17.9', 'spread': '5.2', 'groupId': 'OG000'}, {'value': '12.7', 'spread': '5.0', 'groupId': 'OG001'}]}]}, {'title': '45 mg Cocaine', 'categories': [{'measurements': [{'value': '21.4', 'spread': '7.0', 'groupId': 'OG000'}, {'value': '27.2', 'spread': '6.0', 'groupId': 'OG001'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Subjects completed this measure at 15 minute intervals for 45 minutes after sampling each cocaine dose under both buspirone and placebo maintenance conditions.', 'description': 'Subjects rated their feelings of "High" on a Visual Analog Scale. This item was rated from 0 (minimum)-100 (maximum) on a Visual Analog Scale. Higher values represent greater subjective effects on this item. Peak scores were calculated from multiple assessments for each cocaine dose under both buspirone and placebo conditions.', 'unitOfMeasure': 'arbitary units on a Visual Analog Scale', 'dispersionType': 'Standard Error', 'reportingStatus': 'POSTED'}, {'type': 'SECONDARY', 'title': 'Peak Ratings of "Irregular/Racing Heartbeat" on the Visual Analog Scale', 'denoms': [{'units': 'Participants', 'counts': [{'value': '9', 'groupId': 'OG000'}, {'value': '9', 'groupId': 'OG001'}]}], 'groups': [{'id': 'OG000', 'title': 'Buspirone', 'description': 'Subjects were maintained on 30 mg buspirone daily for 6 days.'}, {'id': 'OG001', 'title': 'Placebo', 'description': 'Subjects were maintained on placebo daily for 6 days.'}], 'classes': [{'title': '0 mg Cocaine', 'categories': [{'measurements': [{'value': '3.9', 'spread': '3.3', 'groupId': 'OG000'}, {'value': '2.3', 'spread': '1.3', 'groupId': 'OG001'}]}]}, {'title': '15 mg Cocaine', 'categories': [{'measurements': [{'value': '11.1', 'spread': '6.3', 'groupId': 'OG000'}, {'value': '9.1', 'spread': '6.0', 'groupId': 'OG001'}]}]}, {'title': '45 mg Cocaine', 'categories': [{'measurements': [{'value': '20.1', 'spread': '8.4', 'groupId': 'OG000'}, {'value': '14.3', 'spread': '4.8', 'groupId': 'OG001'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Subjects completed this measure at 15 minute intervals for 45 minutes after sampling each cocaine dose under both buspirone and placebo maintenance conditions.', 'description': 'Subjects rated their feelings of "Irregular/Racing Heartbeat" on a Visual Analog Scale. This item was rated from 0 (minimum)-100 (maximum) on a Visual Analog Scale. Higher values represent greater subjective effects on this item. Peak scores were calculated from multiple assessments for each cocaine dose under both buspirone and placebo conditions.', 'unitOfMeasure': 'arbitary units on a Visual Analog Scale', 'dispersionType': 'Standard Error', 'reportingStatus': 'POSTED'}, {'type': 'SECONDARY', 'title': 'Peak Ratings of "Like Drug" on the Visual Analog Scale', 'denoms': [{'units': 'Participants', 'counts': [{'value': '9', 'groupId': 'OG000'}, {'value': '9', 'groupId': 'OG001'}]}], 'groups': [{'id': 'OG000', 'title': 'Buspirone', 'description': 'Subjects were maintained on 30 mg buspirone daily for 6 days.'}, {'id': 'OG001', 'title': 'Placebo', 'description': 'Subjects were maintained on placebo daily for 6 days.'}], 'classes': [{'title': '0 mg Cocaine', 'categories': [{'measurements': [{'value': '3.6', 'spread': '2.5', 'groupId': 'OG000'}, {'value': '2.1', 'spread': '1.5', 'groupId': 'OG001'}]}]}, {'title': '15 mg Cocaine', 'categories': [{'measurements': [{'value': '23.9', 'spread': '6.0', 'groupId': 'OG000'}, {'value': '18.3', 'spread': '6.4', 'groupId': 'OG001'}]}]}, {'title': '45 mg Cocaine', 'categories': [{'measurements': [{'value': '30.3', 'spread': '8.4', 'groupId': 'OG000'}, {'value': '36.1', 'spread': '7.8', 'groupId': 'OG001'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Subjects completed this measure at 15 minute intervals for 45 minutes after sampling each cocaine dose under both buspirone and placebo maintenance conditions.', 'description': 'Subjects rated their feelings of "Like Drug" on a Visual Analog Scale. This item was rated from 0 (minimum)-100 (maximum) on a Visual Analog Scale. Higher values represent greater subjective effects on this item. Peak scores were calculated from multiple assessments for each cocaine dose under both buspirone and placebo conditions.', 'unitOfMeasure': 'arbitary units on a Visual Analog Scale', 'dispersionType': 'Standard Error', 'reportingStatus': 'POSTED'}, {'type': 'SECONDARY', 'title': 'Peak Ratings of "Nauseated, Queasy, Sick to Stomach" on the Visual Analog Scale', 'denoms': [{'units': 'Participants', 'counts': [{'value': '9', 'groupId': 'OG000'}, {'value': '9', 'groupId': 'OG001'}]}], 'groups': [{'id': 'OG000', 'title': 'Buspirone', 'description': 'Subjects were maintained on 30 mg buspirone daily for 6 days.'}, {'id': 'OG001', 'title': 'Placebo', 'description': 'Subjects were maintained on placebo daily for 6 days.'}], 'classes': [{'title': '0 mg Cocaine', 'categories': [{'measurements': [{'value': '3.8', 'spread': '3.1', 'groupId': 'OG000'}, {'value': '1.6', 'spread': '1.1', 'groupId': 'OG001'}]}]}, {'title': '15 mg Cocaine', 'categories': [{'measurements': [{'value': '8.8', 'spread': '5.7', 'groupId': 'OG000'}, {'value': '10.6', 'spread': '5.7', 'groupId': 'OG001'}]}]}, {'title': '45 mg Cocaine', 'categories': [{'measurements': [{'value': '13.4', 'spread': '6.3', 'groupId': 'OG000'}, {'value': '11.1', 'spread': '5.4', 'groupId': 'OG001'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Subjects completed this measure at 15 minute intervals for 45 minutes after sampling each cocaine dose under both buspirone and placebo maintenance conditions.', 'description': 'Subjects rated their feelings of "Nauseated, Queasy, Sick to Stomach" on a Visual Analog Scale. This item was rated from 0 (minimum)-100 (maximum) on a Visual Analog Scale. Higher values represent greater subjective effects on this item. Peak scores were calculated from multiple assessments for each cocaine dose under both buspirone and placebo conditions.', 'unitOfMeasure': 'arbitary units on a Visual Analog Scale', 'dispersionType': 'Standard Error', 'reportingStatus': 'POSTED'}, {'type': 'SECONDARY', 'title': 'Peak Ratings of "Nervous, Anxious" on the Visual Analog Scale', 'denoms': [{'units': 'Participants', 'counts': [{'value': '9', 'groupId': 'OG000'}, {'value': '9', 'groupId': 'OG001'}]}], 'groups': [{'id': 'OG000', 'title': 'Buspirone', 'description': 'Subjects were maintained on 30 mg buspirone daily for 6 days.'}, {'id': 'OG001', 'title': 'Placebo', 'description': 'Subjects were maintained on placebo daily for 6 days.'}], 'classes': [{'title': '0 mg Cocaine', 'categories': [{'measurements': [{'value': '3.6', 'spread': '3.0', 'groupId': 'OG000'}, {'value': '2', 'spread': '1.4', 'groupId': 'OG001'}]}]}, {'title': '15 mg Cocaine', 'categories': [{'measurements': [{'value': '13.1', 'spread': '5.8', 'groupId': 'OG000'}, {'value': '10.2', 'spread': '4.6', 'groupId': 'OG001'}]}]}, {'title': '45 mg Cocaine', 'categories': [{'measurements': [{'value': '17.2', 'spread': '7.4', 'groupId': 'OG000'}, {'value': '12.6', 'spread': '5.2', 'groupId': 'OG001'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Subjects completed this measure at 15 minute intervals for 45 minutes after sampling each cocaine dose under both buspirone and placebo maintenance conditions.', 'description': 'Subjects rated their feelings of "Nervous, Anxious" on a Visual Analog Scale. This item was rated from 0 (minimum)-100 (maximum) on a Visual Analog Scale. Higher values represent greater subjective effects on this item. Peak scores were calculated from multiple assessments for each cocaine dose under both buspirone and placebo conditions.', 'unitOfMeasure': 'arbitary units on a Visual Analog Scale', 'dispersionType': 'Standard Error', 'reportingStatus': 'POSTED'}, {'type': 'SECONDARY', 'title': 'Peak Ratings of "Willing to Pay For" on the Visual Analog Scale', 'denoms': [{'units': 'Participants', 'counts': [{'value': '9', 'groupId': 'OG000'}, {'value': '9', 'groupId': 'OG001'}]}], 'groups': [{'id': 'OG000', 'title': 'Buspirone', 'description': 'Subjects were maintained on 30 mg buspirone daily for 6 days.'}, {'id': 'OG001', 'title': 'Placebo', 'description': 'Subjects were maintained on placebo daily for 6 days.'}], 'classes': [{'title': '0 mg Cocaine', 'categories': [{'measurements': [{'value': '3.6', 'spread': '2.7', 'groupId': 'OG000'}, {'value': '3.1', 'spread': '2.4', 'groupId': 'OG001'}]}]}, {'title': '15 mg Cocaine', 'categories': [{'measurements': [{'value': '18.6', 'spread': '5.4', 'groupId': 'OG000'}, {'value': '13.9', 'spread': '4.5', 'groupId': 'OG001'}]}]}, {'title': '45 mg Cocaine', 'categories': [{'measurements': [{'value': '31.9', 'spread': '10.9', 'groupId': 'OG000'}, {'value': '31.3', 'spread': '8.8', 'groupId': 'OG001'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Subjects completed this measure at 15 minute intervals for 45 minutes after sampling each cocaine dose under both buspirone and placebo maintenance conditions.', 'description': 'Subjects rated their feelings of "Willing to Pay For" on a Visual Analog Scale. This item was rated from 0 (minimum)-100 (maximum) on a Visual Analog Scale. Higher values represent greater subjective effects on this item. Peak scores were calculated from multiple assessments for each cocaine dose under both buspirone and placebo conditions.', 'unitOfMeasure': 'arbitary units on a Visual Analog Scale', 'dispersionType': 'Standard Error', 'reportingStatus': 'POSTED'}, {'type': 'SECONDARY', 'title': 'Peak Ratings of "Performance Impaired" on the Visual Analog Scale', 'denoms': [{'units': 'Participants', 'counts': [{'value': '9', 'groupId': 'OG000'}, {'value': '9', 'groupId': 'OG001'}]}], 'groups': [{'id': 'OG000', 'title': 'Buspirone', 'description': 'Subjects were maintained on 30 mg buspirone daily for 6 days.'}, {'id': 'OG001', 'title': 'Placebo', 'description': 'Subjects were maintained on placebo daily for 6 days.'}], 'classes': [{'title': '0 mg Cocaine', 'categories': [{'measurements': [{'value': '2.6', 'spread': '2.1', 'groupId': 'OG000'}, {'value': '4.3', 'spread': '2.5', 'groupId': 'OG001'}]}]}, {'title': '15 mg Cocaine', 'categories': [{'measurements': [{'value': '8.8', 'spread': '5.2', 'groupId': 'OG000'}, {'value': '6.3', 'spread': '3.3', 'groupId': 'OG001'}]}]}, {'title': '45 mg Cocaine', 'categories': [{'measurements': [{'value': '12.6', 'spread': '6.8', 'groupId': 'OG000'}, {'value': '18.2', 'spread': '8.4', 'groupId': 'OG001'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Subjects completed this measure at 15 minute intervals for 45 minutes after sampling each cocaine dose under both buspirone and placebo maintenance conditions.', 'description': 'Subjects rated their feelings of "Performance Impaired" on a Visual Analog Scale. This item was rated from 0 (minimum)-100 (maximum) on a Visual Analog Scale. Higher values represent greater subjective effects on this item. Peak scores were calculated from multiple assessments for each cocaine dose under both buspirone and placebo conditions.', 'unitOfMeasure': 'arbitary units on a Visual Analog Scale', 'dispersionType': 'Standard Error', 'reportingStatus': 'POSTED'}, {'type': 'SECONDARY', 'title': 'Peak Ratings of "Performance Improved" on the Visual Analog Scale', 'denoms': [{'units': 'Participants', 'counts': [{'value': '9', 'groupId': 'OG000'}, {'value': '9', 'groupId': 'OG001'}]}], 'groups': [{'id': 'OG000', 'title': 'Buspirone', 'description': 'Subjects were maintained on 30 mg buspirone daily for 6 days.'}, {'id': 'OG001', 'title': 'Placebo', 'description': 'Subjects were maintained on placebo daily for 6 days.'}], 'classes': [{'title': '0 mg Cocaine', 'categories': [{'measurements': [{'value': '2.7', 'spread': '1.9', 'groupId': 'OG000'}, {'value': '1.9', 'spread': '1.3', 'groupId': 'OG001'}]}]}, {'title': '15 mg Cocaine', 'categories': [{'measurements': [{'value': '8.9', 'spread': '5.6', 'groupId': 'OG000'}, {'value': '5.2', 'spread': '2.8', 'groupId': 'OG001'}]}]}, {'title': '45 mg Cocaine', 'categories': [{'measurements': [{'value': '4.7', 'spread': '3.1', 'groupId': 'OG000'}, {'value': '4.8', 'spread': '2.7', 'groupId': 'OG001'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Subjects completed this measure at 15 minute intervals for 45 minutes after sampling each cocaine dose under both buspirone and placebo maintenance conditions.', 'description': 'Subjects rated their feelings of "Performance Improved" on a Visual Analog Scale. This item was rated from 0 (minimum)-100 (maximum) on a Visual Analog Scale. Higher values represent greater subjective effects on this item. Peak scores were calculated from multiple assessments for each cocaine dose under both buspirone and placebo conditions.', 'unitOfMeasure': 'arbitary units on a Visual Analog Scale', 'dispersionType': 'Standard Error', 'reportingStatus': 'POSTED'}, {'type': 'SECONDARY', 'title': 'Peak Ratings of "Restless" on the Visual Analog Scale', 'denoms': [{'units': 'Participants', 'counts': [{'value': '9', 'groupId': 'OG000'}, {'value': '9', 'groupId': 'OG001'}]}], 'groups': [{'id': 'OG000', 'title': 'Buspirone', 'description': 'Subjects were maintained on 30 mg buspirone daily for 6 days.'}, {'id': 'OG001', 'title': 'Placebo', 'description': 'Subjects were maintained on placebo daily for 6 days.'}], 'classes': [{'title': '0 mg Cocaine', 'categories': [{'measurements': [{'value': '4.1', 'spread': '3.6', 'groupId': 'OG000'}, {'value': '1.9', 'spread': '1.2', 'groupId': 'OG001'}]}]}, {'title': '15 mg Cocaine', 'categories': [{'measurements': [{'value': '10.0', 'spread': '6.3', 'groupId': 'OG000'}, {'value': '10.2', 'spread': '5.0', 'groupId': 'OG001'}]}]}, {'title': '45 mg Cocaine', 'categories': [{'measurements': [{'value': '13.0', 'spread': '6.4', 'groupId': 'OG000'}, {'value': '9.4', 'spread': '4.4', 'groupId': 'OG001'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Subjects completed this measure at 15 minute intervals for 45 minutes after sampling each cocaine dose under both buspirone and placebo maintenance conditions.', 'description': 'Subjects rated their feelings of "Restless" on a Visual Analog Scale. This item was rated from 0 (minimum)-100 (maximum) on a Visual Analog Scale. Higher values represent greater subjective effects on this item. Peak scores were calculated from multiple assessments for each cocaine dose under both buspirone and placebo conditions.', 'unitOfMeasure': 'arbitary units on a Visual Analog Scale', 'dispersionType': 'Standard Error', 'reportingStatus': 'POSTED'}, {'type': 'SECONDARY', 'title': 'Peak Ratings of "Rush" on the Visual Analog Scale', 'denoms': [{'units': 'Participants', 'counts': [{'value': '9', 'groupId': 'OG000'}, {'value': '9', 'groupId': 'OG001'}]}], 'groups': [{'id': 'OG000', 'title': 'Buspirone', 'description': 'Subjects were maintained on 30 mg buspirone daily for 6 days.'}, {'id': 'OG001', 'title': 'Placebo', 'description': 'Subjects were maintained on placebo daily for 6 days.'}], 'classes': [{'title': '0 mg Cocaine', 'categories': [{'measurements': [{'value': '3.6', 'spread': '2.8', 'groupId': 'OG000'}, {'value': '1.9', 'spread': '1.3', 'groupId': 'OG001'}]}]}, {'title': '15 mg Cocaine', 'categories': [{'measurements': [{'value': '18.4', 'spread': '5.1', 'groupId': 'OG000'}, {'value': '12.4', 'spread': '4.1', 'groupId': 'OG001'}]}]}, {'title': '45 mg Cocaine', 'categories': [{'measurements': [{'value': '20.1', 'spread': '5.8', 'groupId': 'OG000'}, {'value': '23.3', 'spread': '6.2', 'groupId': 'OG001'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Subjects completed this measure at 15 minute intervals for 45 minutes after sampling each cocaine dose under both buspirone and placebo maintenance conditions.', 'description': 'Subjects rated their feelings of "Rush" on a Visual Analog Scale. This item was rated from 0 (minimum)-100 (maximum) on a Visual Analog Scale. Higher values represent greater subjective effects on this item. Peak scores were calculated from multiple assessments for each cocaine dose under both buspirone and placebo conditions.', 'unitOfMeasure': 'arbitary units on a Visual Analog Scale', 'dispersionType': 'Standard Error', 'reportingStatus': 'POSTED'}, {'type': 'SECONDARY', 'title': 'Peak Ratings of "Shaky, Jittery" on the Visual Analog Scale', 'denoms': [{'units': 'Participants', 'counts': [{'value': '9', 'groupId': 'OG000'}, {'value': '9', 'groupId': 'OG001'}]}], 'groups': [{'id': 'OG000', 'title': 'Buspirone', 'description': 'Subjects were maintained on 30 mg buspirone daily for 6 days.'}, {'id': 'OG001', 'title': 'Placebo', 'description': 'Subjects were maintained on placebo daily for 6 days.'}], 'classes': [{'title': '0 mg Cocaine', 'categories': [{'measurements': [{'value': '4.8', 'spread': '4.1', 'groupId': 'OG000'}, {'value': '2.1', 'spread': '1.5', 'groupId': 'OG001'}]}]}, {'title': '15 mg Cocaine', 'categories': [{'measurements': [{'value': '15.1', 'spread': '6.0', 'groupId': 'OG000'}, {'value': '11.4', 'spread': '5.2', 'groupId': 'OG001'}]}]}, {'title': '45 mg Cocaine', 'categories': [{'measurements': [{'value': '18.9', 'spread': '8.2', 'groupId': 'OG000'}, {'value': '17.7', 'spread': '5.3', 'groupId': 'OG001'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Subjects completed this measure at 15 minute intervals for 45 minutes after sampling each cocaine dose under both buspirone and placebo maintenance conditions.', 'description': 'Subjects rated their feelings of "Shaky, Jittery" on a Visual Analog Scale. This item was rated from 0 (minimum)-100 (maximum) on a Visual Analog Scale. Higher values represent greater subjective effects on this item. Peak scores were calculated from multiple assessments for each cocaine dose under both buspirone and placebo conditions.', 'unitOfMeasure': 'arbitary units on a Visual Analog Scale', 'dispersionType': 'Standard Error', 'reportingStatus': 'POSTED'}, {'type': 'SECONDARY', 'title': 'Peak Ratings of "Sluggish, Fatigued, Lazy" on the Visual Analog Scale', 'denoms': [{'units': 'Participants', 'counts': [{'value': '9', 'groupId': 'OG000'}, {'value': '9', 'groupId': 'OG001'}]}], 'groups': [{'id': 'OG000', 'title': 'Buspirone', 'description': 'Subjects were maintained on 30 mg buspirone daily for 6 days.'}, {'id': 'OG001', 'title': 'Placebo', 'description': 'Subjects were maintained on placebo daily for 6 days.'}], 'classes': [{'title': '0 mg Cocaine', 'categories': [{'measurements': [{'value': '5.3', 'spread': '4.2', 'groupId': 'OG000'}, {'value': '12.9', 'spread': '8.3', 'groupId': 'OG001'}]}]}, {'title': '15 mg Cocaine', 'categories': [{'measurements': [{'value': '13.4', 'spread': '8.0', 'groupId': 'OG000'}, {'value': '12.7', 'spread': '6.7', 'groupId': 'OG001'}]}]}, {'title': '45 mg Cocaine', 'categories': [{'measurements': [{'value': '12.9', 'spread': '6.8', 'groupId': 'OG000'}, {'value': '7.7', 'spread': '5.1', 'groupId': 'OG001'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Subjects completed this measure at 15 minute intervals for 45 minutes after sampling each cocaine dose under both buspirone and placebo maintenance conditions.', 'description': 'Subjects rated their feelings of "Sluggish, Fatigued, Lazy" on a Visual Analog Scale. This item was rated from 0 (minimum)-100 (maximum) on a Visual Analog Scale. Higher values represent greater subjective effects on this item. Peak scores were calculated from multiple assessments for each cocaine dose under both buspirone and placebo conditions.', 'unitOfMeasure': 'arbitary units on a Visual Analog Scale', 'dispersionType': 'Standard Error', 'reportingStatus': 'POSTED'}, {'type': 'SECONDARY', 'title': 'Peak Ratings of "Stimulated" on the Visual Analog Scale', 'denoms': [{'units': 'Participants', 'counts': [{'value': '9', 'groupId': 'OG000'}, {'value': '9', 'groupId': 'OG001'}]}], 'groups': [{'id': 'OG000', 'title': 'Buspirone', 'description': 'Subjects were maintained on 30 mg buspirone daily for 6 days.'}, {'id': 'OG001', 'title': 'Placebo', 'description': 'Subjects were maintained on placebo daily for 6 days.'}], 'classes': [{'title': '0 mg Cocaine', 'categories': [{'measurements': [{'value': '4.0', 'spread': '3.1', 'groupId': 'OG000'}, {'value': '4.2', 'spread': '3.3', 'groupId': 'OG001'}]}]}, {'title': '15 mg Cocaine', 'categories': [{'measurements': [{'value': '18.7', 'spread': '5.6', 'groupId': 'OG000'}, {'value': '17.9', 'spread': '5.7', 'groupId': 'OG001'}]}]}, {'title': '45 mg Cocaine', 'categories': [{'measurements': [{'value': '25.3', 'spread': '7.6', 'groupId': 'OG000'}, {'value': '32.3', 'spread': '8.5', 'groupId': 'OG001'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Subjects completed this measure at 15 minute intervals for 45 minutes after sampling each cocaine dose under both buspirone and placebo maintenance conditions.', 'description': 'Subjects rated their feelings of "Stimulated" on a Visual Analog Scale. This item was rated from 0 (minimum)-100 (maximum) on a Visual Analog Scale. Higher values represent greater subjective effects on this item. Peak scores were calculated from multiple assessments for each cocaine dose under both buspirone and placebo conditions.', 'unitOfMeasure': 'arbitary units on a Visual Analog Scale', 'dispersionType': 'Standard Error', 'reportingStatus': 'POSTED'}, {'type': 'SECONDARY', 'title': 'Peak Ratings of "Willing to Take Again" on the Visual Analog Scale', 'denoms': [{'units': 'Participants', 'counts': [{'value': '9', 'groupId': 'OG000'}, {'value': '9', 'groupId': 'OG001'}]}], 'groups': [{'id': 'OG000', 'title': 'Buspirone', 'description': 'Subjects were maintained on 30 mg buspirone daily for 6 days.'}, {'id': 'OG001', 'title': 'Placebo', 'description': 'Subjects were maintained on placebo daily for 6 days.'}], 'classes': [{'title': '0 mg Cocaine', 'categories': [{'measurements': [{'value': '3.3', 'spread': '2.4', 'groupId': 'OG000'}, {'value': '3.2', 'spread': '2.5', 'groupId': 'OG001'}]}]}, {'title': '15 mg Cocaine', 'categories': [{'measurements': [{'value': '27.7', 'spread': '8.4', 'groupId': 'OG000'}, {'value': '22.1', 'spread': '8.3', 'groupId': 'OG001'}]}]}, {'title': '45 mg Cocaine', 'categories': [{'measurements': [{'value': '34.6', 'spread': '11.0', 'groupId': 'OG000'}, {'value': '43.4', 'spread': '10.5', 'groupId': 'OG001'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Subjects completed this measure at 15 minute intervals for 45 minutes after sampling each cocaine dose under both buspirone and placebo maintenance conditions.', 'description': 'Subjects rated their feelings of "Willing to Take Again" on a Visual Analog Scale. This item was rated from 0 (minimum)-100 (maximum) on a Visual Analog Scale. Higher values represent greater subjective effects on this item. Peak scores were calculated from multiple assessments for each cocaine dose under both buspirone and placebo conditions.', 'unitOfMeasure': 'arbitary units on a Visual Analog Scale', 'dispersionType': 'Standard Error', 'reportingStatus': 'POSTED'}, {'type': 'SECONDARY', 'title': 'Peak Ratings of "Talkative, Friendly" on the Visual Analog Scale', 'denoms': [{'units': 'Participants', 'counts': [{'value': '9', 'groupId': 'OG000'}, {'value': '9', 'groupId': 'OG001'}]}], 'groups': [{'id': 'OG000', 'title': 'Buspirone', 'description': 'Subjects were maintained on 30 mg buspirone daily for 6 days.'}, {'id': 'OG001', 'title': 'Placebo', 'description': 'Subjects were maintained on placebo daily for 6 days.'}], 'classes': [{'title': '0 mg Cocaine', 'categories': [{'measurements': [{'value': '3.2', 'spread': '2.6', 'groupId': 'OG000'}, {'value': '2.0', 'spread': '1.3', 'groupId': 'OG001'}]}]}, {'title': '15 mg Cocaine', 'categories': [{'measurements': [{'value': '11.7', 'spread': '5.3', 'groupId': 'OG000'}, {'value': '11.2', 'spread': '4.8', 'groupId': 'OG001'}]}]}, {'title': '45 mg Cocaine', 'categories': [{'measurements': [{'value': '12.1', 'spread': '4.6', 'groupId': 'OG000'}, {'value': '21.8', 'spread': '8.0', 'groupId': 'OG001'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Subjects completed this measure at 15 minute intervals for 45 minutes after sampling each cocaine dose under both buspirone and placebo maintenance conditions.', 'description': 'Subjects rated their feelings of "Talkative, Friendly" on a Visual Analog Scale. This item was rated from 0 (minimum)-100 (maximum) on a Visual Analog Scale. Higher values represent greater subjective effects on this item. Peak scores were calculated from multiple assessments for each cocaine dose under both buspirone and placebo conditions.', 'unitOfMeasure': 'arbitary units on a Visual Analog Scale', 'dispersionType': 'Standard Error', 'reportingStatus': 'POSTED'}, {'type': 'SECONDARY', 'title': 'Peak Oral Temperature', 'denoms': [{'units': 'Participants', 'counts': [{'value': '9', 'groupId': 'OG000'}, {'value': '9', 'groupId': 'OG001'}]}], 'groups': [{'id': 'OG000', 'title': 'Buspirone', 'description': 'Subjects were maintained on 30 mg buspirone daily for 6 days.'}, {'id': 'OG001', 'title': 'Placebo', 'description': 'Subjects were maintained on placebo daily for 6 days.'}], 'classes': [{'title': '0 mg Cocaine', 'categories': [{'measurements': [{'value': '98.2', 'spread': '0.1', 'groupId': 'OG000'}, {'value': '98.3', 'spread': '0.2', 'groupId': 'OG001'}]}]}, {'title': '15 mg Cocaine', 'categories': [{'measurements': [{'value': '98.3', 'spread': '0.1', 'groupId': 'OG000'}, {'value': '98.4', 'spread': '0.2', 'groupId': 'OG001'}]}]}, {'title': '45 mg Cocaine', 'categories': [{'measurements': [{'value': '98.1', 'spread': '0.1', 'groupId': 'OG000'}, {'value': '98.4', 'spread': '0.1', 'groupId': 'OG001'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'This measure was completed at 15 minute intervals for 45 minutes after sampling each cocaine dose under both buspirone and placebo maintenance conditions.', 'description': 'Oral temperature was measured with an automated monitor. Higher values represent greater temperature. Peak scores were calculated from multiple assessments for each cocaine dose under both buspirone and placebo conditions.', 'unitOfMeasure': 'Degrees Fahrenheit', 'dispersionType': 'Standard Error', 'reportingStatus': 'POSTED'}, {'type': 'SECONDARY', 'title': 'Peak Diastolic Blood Pressure', 'denoms': [{'units': 'Participants', 'counts': [{'value': '9', 'groupId': 'OG000'}, {'value': '9', 'groupId': 'OG001'}]}], 'groups': [{'id': 'OG000', 'title': 'Buspirone', 'description': 'Subjects were maintained on 30 mg buspirone daily for 6 days.'}, {'id': 'OG001', 'title': 'Placebo', 'description': 'Subjects were maintained on placebo daily for 6 days.'}], 'classes': [{'title': '0 mg Cocaine', 'categories': [{'measurements': [{'value': '74.3', 'spread': '2.1', 'groupId': 'OG000'}, {'value': '73.3', 'spread': '3.1', 'groupId': 'OG001'}]}]}, {'title': '15 mg Cocaine', 'categories': [{'measurements': [{'value': '75.1', 'spread': '2.5', 'groupId': 'OG000'}, {'value': '74.6', 'spread': '2.8', 'groupId': 'OG001'}]}]}, {'title': '45 mg Cocaine', 'categories': [{'measurements': [{'value': '77.6', 'spread': '2.7', 'groupId': 'OG000'}, {'value': '77.6', 'spread': '2.4', 'groupId': 'OG001'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'This measure was completed at 15 minute intervals for 45 minutes after sampling each cocaine dose under both buspirone and placebo maintenance conditions.', 'description': 'Diastolic blood pressure was measured with an automated monitor. Higher values represent greater diastolic pressure. Peak scores were calculated from multiple assessments for each cocaine dose under both buspirone and placebo conditions.', 'unitOfMeasure': 'mmHg', 'dispersionType': 'Standard Error', 'reportingStatus': 'POSTED'}, {'type': 'SECONDARY', 'title': 'Peak Heart Rate', 'denoms': [{'units': 'Participants', 'counts': [{'value': '9', 'groupId': 'OG000'}, {'value': '9', 'groupId': 'OG001'}]}], 'groups': [{'id': 'OG000', 'title': 'Buspirone', 'description': 'Subjects were maintained on 30 mg buspirone daily for 6 days.'}, {'id': 'OG001', 'title': 'Placebo', 'description': 'Subjects were maintained on placebo daily for 6 days.'}], 'classes': [{'title': '0 mg Cocaine', 'categories': [{'measurements': [{'value': '75.9', 'spread': '3.6', 'groupId': 'OG000'}, {'value': '79.7', 'spread': '3.6', 'groupId': 'OG001'}]}]}, {'title': '15 mg Cocaine', 'categories': [{'measurements': [{'value': '79.9', 'spread': '3.8', 'groupId': 'OG000'}, {'value': '79.6', 'spread': '4.6', 'groupId': 'OG001'}]}]}, {'title': '45 mg Cocaine', 'categories': [{'measurements': [{'value': '82.8', 'spread': '2.7', 'groupId': 'OG000'}, {'value': '89.3', 'spread': '5.4', 'groupId': 'OG001'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'This measure was completed at 15 minute intervals for 45 minutes after sampling each cocaine dose under both buspirone and placebo maintenance conditions.', 'description': 'Heart rate was measured with an automated monitor. Higher values represent greater heart rate. Peak scores were calculated from multiple assessments for each cocaine dose under both buspirone and placebo conditions.', 'unitOfMeasure': 'beats per minute', 'dispersionType': 'Standard Error', 'reportingStatus': 'POSTED'}]}, 'participantFlowModule': {'groups': [{'id': 'FG000', 'title': 'Buspirone Then Placebo', 'description': 'Subjects were maintained on 30 mg buspirone daily for 6 days, then they were crossed over to placebo daily for 6 days.'}, {'id': 'FG001', 'title': 'Placebo Then Buspirone', 'description': 'Subjects were maintained on placebo daily for 6 days, then they were crossed over to 30 mg buspirone daily for 6 days.'}], 'periods': [{'title': 'Overall Study', 'milestones': [{'type': 'STARTED', 'achievements': [{'groupId': 'FG000', 'numSubjects': '4'}, {'groupId': 'FG001', 'numSubjects': '5'}]}, {'type': 'COMPLETED', 'achievements': [{'groupId': 'FG000', 'numSubjects': '4'}, {'groupId': 'FG001', 'numSubjects': '5'}]}, {'type': 'NOT COMPLETED', 'achievements': [{'groupId': 'FG000', 'numSubjects': '0'}, {'groupId': 'FG001', 'numSubjects': '0'}]}]}]}, 'baselineCharacteristicsModule': {'denoms': [{'units': 'Participants', 'counts': [{'value': '9', 'groupId': 'BG000'}]}], 'groups': [{'id': 'BG000', 'title': 'All Study Participants', 'description': 'Subjects were maintained on oral buspirone (10 mg administered 3 times daily) or placebo for 6 days each during the study in random order.'}], 'measures': [{'title': 'Age, Continuous', 'classes': [{'categories': [{'measurements': [{'value': '39.4', 'groupId': 'BG000', 'lowerLimit': '26', 'upperLimit': '48'}]}]}], 'paramType': 'MEAN', 'unitOfMeasure': 'years', 'dispersionType': 'FULL_RANGE'}, {'title': 'Sex: Female, Male', 'classes': [{'categories': [{'title': 'Female', 'measurements': [{'value': '2', 'groupId': 'BG000'}]}, {'title': 'Male', 'measurements': [{'value': '7', 'groupId': 'BG000'}]}]}], 'paramType': 'COUNT_OF_PARTICIPANTS', 'unitOfMeasure': 'Participants'}, {'title': 'Region of Enrollment', 'classes': [{'title': 'United States', 'categories': [{'measurements': [{'value': '9', 'groupId': 'BG000'}]}]}], 'paramType': 'NUMBER', 'unitOfMeasure': 'participants'}]}}, 'protocolSection': {'designModule': {'phases': ['NA'], 'studyType': 'INTERVENTIONAL', 'designInfo': {'allocation': 'RANDOMIZED', 'maskingInfo': {'masking': 'TRIPLE', 'whoMasked': ['PARTICIPANT', 'CARE_PROVIDER', 'OUTCOMES_ASSESSOR']}, 'primaryPurpose': 'BASIC_SCIENCE', 'interventionModel': 'CROSSOVER'}, 'enrollmentInfo': {'type': 'ACTUAL', 'count': 9}}, 'statusModule': {'overallStatus': 'COMPLETED', 'startDateStruct': {'date': '2012-09'}, 'expandedAccessInfo': {'hasExpandedAccess': False}, 'statusVerifiedDate': '2016-01', 'completionDateStruct': {'date': '2014-12', 'type': 'ACTUAL'}, 'lastUpdateSubmitDate': '2016-01-22', 'studyFirstSubmitDate': '2012-07-10', 'resultsFirstSubmitDate': '2015-12-04', 'studyFirstSubmitQcDate': '2012-07-11', 'lastUpdatePostDateStruct': {'date': '2016-02-19', 'type': 'ESTIMATED'}, 'resultsFirstSubmitQcDate': '2016-01-22', 'studyFirstPostDateStruct': {'date': '2012-07-12', 'type': 'ESTIMATED'}, 'resultsFirstPostDateStruct': {'date': '2016-02-19', 'type': 'ESTIMATED'}, 'primaryCompletionDateStruct': {'date': '2014-12', 'type': 'ACTUAL'}}, 'outcomesModule': {'primaryOutcomes': [{'measure': 'Number of Times Cocaine Was Selected in the Presence of a Monetary Reward Alternative', 'timeFrame': 'One test per cocaine dose level per intervention for each participant over his/her 2 week inpatient admission', 'description': 'The reinforcing effects of cocaine were determined using a modified progressive ratio procedure (Stoops et al., 2010) in which subjects made 6 choices between available each available cocaine dose and money (US$0.25). Reinforcing effects are measured for each cocaine dose during both buspirone and placebo maintenance.'}], 'secondaryOutcomes': [{'measure': 'Peak Score on Sedative Subscale of the Adjective Rating Scale', 'timeFrame': 'Subjects completed this measure at 15 minute intervals for 45 minutes after sampling each cocaine dose under both buspirone and placebo maintenance conditions.', 'description': 'Subjects completed 16 items that loaded into the Sedative Subscale of the Adjective Rating Scale. The items were rated 0-4 on a Likert-type scale and the sum for the 16 "sedative" items was summed to yield the Sedative Subscale score. The maximum score for this scale was 64, the minimum was 0. Higher values represent greater subjective effects on this item. Peak scores were calculated from multiple assessments for each cocaine dose under both buspirone and placebo conditions.'}, {'measure': 'Peak Systolic Blood Pressure', 'timeFrame': 'This measure was completed at 15 minute intervals for 45 minutes after sampling each cocaine dose under both buspirone and placebo maintenance conditions.', 'description': 'Systolic blood pressure was measured with an automated monitor. Higher values represent greater systolic pressure. Peak scores were calculated from multiple assessments for each cocaine dose under both buspirone and placebo conditions.'}, {'measure': 'Peak Score on Stimulant Subscale of the Adjective Rating Scale', 'timeFrame': 'Subjects completed this measure at 15 minute intervals for 45 minutes after sampling each cocaine dose under both buspirone and placebo maintenance conditions.', 'description': 'Subjects completed 16 items that loaded into the Stimulant Subscale of the Adjective Rating Scale. The items were rated 0-4 on a Likert-type scale and the sum for the 16 "sedative" items was summed to yield the Stimulant Subscale score. The maximum score for this scale was 64, the minimum was 0. Higher values represent greater subjective effects on this item. Peak scores were calculated from multiple assessments for each cocaine dose under both buspirone and placebo conditions.'}, {'measure': 'Peak Ratings of "Active, Alert, Energetic" on the Visual Analog Scale', 'timeFrame': 'Subjects completed this measure at 15 minute intervals for 45 minutes after sampling each cocaine dose under both buspirone and placebo maintenance conditions.', 'description': 'Subjects rated their feelings of "Active, Alert, Energetic" on a Visual Analog Scale. This item was rated from 0 (minimum)-100 (maximum) on a Visual Analog Scale. Higher values represent greater subjective effects on this item. Peak scores were calculated from multiple assessments for each cocaine dose under both buspirone and placebo conditions.'}, {'measure': 'Peak Ratings of "Any Effect" on the Visual Analog Scale', 'timeFrame': 'Subjects completed this measure at 15 minute intervals for 45 minutes after sampling each cocaine dose under both buspirone and placebo maintenance conditions.', 'description': 'Subjects rated their feelings of "Any Effect" on a Visual Analog Scale. This item was rated from 0 (minimum)-100 (maximum) on a Visual Analog Scale. Higher values represent greater subjective effects on this item. Peak scores were calculated from multiple assessments for each cocaine dose under both buspirone and placebo conditions.'}, {'measure': 'Peak Ratings of "Bad Effects" on the Visual Analog Scale', 'timeFrame': 'Subjects completed this measure at 15 minute intervals for 45 minutes after sampling each cocaine dose under both buspirone and placebo maintenance conditions.', 'description': 'Subjects rated their feelings of "Bad Effects" on a Visual Analog Scale. This item was rated from 0 (minimum)-100 (maximum) on a Visual Analog Scale. Higher values represent greater subjective effects on this item. Peak scores were calculated from multiple assessments for each cocaine dose under both buspirone and placebo conditions.'}, {'measure': 'Peak Ratings of "Euphoric" on the Visual Analog Scale', 'timeFrame': 'Subjects completed this measure at 15 minute intervals for 45 minutes after sampling each cocaine dose under both buspirone and placebo maintenance conditions.', 'description': 'Subjects rated their feelings of "Euphoric" on a Visual Analog Scale. This item was rated from 0 (minimum)-100 (maximum) on a Visual Analog Scale. Higher values represent greater subjective effects on this item. Peak scores were calculated from multiple assessments for each cocaine dose under both buspirone and placebo conditions.'}, {'measure': 'Peak Ratings of "Good Effects" on the Visual Analog Scale', 'timeFrame': 'Subjects completed this measure at 15 minute intervals for 45 minutes after sampling each cocaine dose under both buspirone and placebo maintenance conditions.', 'description': 'Subjects rated their feelings of "Good Effects" on a Visual Analog Scale. This item was rated from 0 (minimum)-100 (maximum) on a Visual Analog Scale. Higher values represent greater subjective effects on this item. Peak scores were calculated from multiple assessments for each cocaine dose under both buspirone and placebo conditions.'}, {'measure': 'Peak Ratings of "High" on the Visual Analog Scale', 'timeFrame': 'Subjects completed this measure at 15 minute intervals for 45 minutes after sampling each cocaine dose under both buspirone and placebo maintenance conditions.', 'description': 'Subjects rated their feelings of "High" on a Visual Analog Scale. This item was rated from 0 (minimum)-100 (maximum) on a Visual Analog Scale. Higher values represent greater subjective effects on this item. Peak scores were calculated from multiple assessments for each cocaine dose under both buspirone and placebo conditions.'}, {'measure': 'Peak Ratings of "Irregular/Racing Heartbeat" on the Visual Analog Scale', 'timeFrame': 'Subjects completed this measure at 15 minute intervals for 45 minutes after sampling each cocaine dose under both buspirone and placebo maintenance conditions.', 'description': 'Subjects rated their feelings of "Irregular/Racing Heartbeat" on a Visual Analog Scale. This item was rated from 0 (minimum)-100 (maximum) on a Visual Analog Scale. Higher values represent greater subjective effects on this item. Peak scores were calculated from multiple assessments for each cocaine dose under both buspirone and placebo conditions.'}, {'measure': 'Peak Ratings of "Like Drug" on the Visual Analog Scale', 'timeFrame': 'Subjects completed this measure at 15 minute intervals for 45 minutes after sampling each cocaine dose under both buspirone and placebo maintenance conditions.', 'description': 'Subjects rated their feelings of "Like Drug" on a Visual Analog Scale. This item was rated from 0 (minimum)-100 (maximum) on a Visual Analog Scale. Higher values represent greater subjective effects on this item. Peak scores were calculated from multiple assessments for each cocaine dose under both buspirone and placebo conditions.'}, {'measure': 'Peak Ratings of "Nauseated, Queasy, Sick to Stomach" on the Visual Analog Scale', 'timeFrame': 'Subjects completed this measure at 15 minute intervals for 45 minutes after sampling each cocaine dose under both buspirone and placebo maintenance conditions.', 'description': 'Subjects rated their feelings of "Nauseated, Queasy, Sick to Stomach" on a Visual Analog Scale. This item was rated from 0 (minimum)-100 (maximum) on a Visual Analog Scale. Higher values represent greater subjective effects on this item. Peak scores were calculated from multiple assessments for each cocaine dose under both buspirone and placebo conditions.'}, {'measure': 'Peak Ratings of "Nervous, Anxious" on the Visual Analog Scale', 'timeFrame': 'Subjects completed this measure at 15 minute intervals for 45 minutes after sampling each cocaine dose under both buspirone and placebo maintenance conditions.', 'description': 'Subjects rated their feelings of "Nervous, Anxious" on a Visual Analog Scale. This item was rated from 0 (minimum)-100 (maximum) on a Visual Analog Scale. Higher values represent greater subjective effects on this item. Peak scores were calculated from multiple assessments for each cocaine dose under both buspirone and placebo conditions.'}, {'measure': 'Peak Ratings of "Willing to Pay For" on the Visual Analog Scale', 'timeFrame': 'Subjects completed this measure at 15 minute intervals for 45 minutes after sampling each cocaine dose under both buspirone and placebo maintenance conditions.', 'description': 'Subjects rated their feelings of "Willing to Pay For" on a Visual Analog Scale. This item was rated from 0 (minimum)-100 (maximum) on a Visual Analog Scale. Higher values represent greater subjective effects on this item. Peak scores were calculated from multiple assessments for each cocaine dose under both buspirone and placebo conditions.'}, {'measure': 'Peak Ratings of "Performance Impaired" on the Visual Analog Scale', 'timeFrame': 'Subjects completed this measure at 15 minute intervals for 45 minutes after sampling each cocaine dose under both buspirone and placebo maintenance conditions.', 'description': 'Subjects rated their feelings of "Performance Impaired" on a Visual Analog Scale. This item was rated from 0 (minimum)-100 (maximum) on a Visual Analog Scale. Higher values represent greater subjective effects on this item. Peak scores were calculated from multiple assessments for each cocaine dose under both buspirone and placebo conditions.'}, {'measure': 'Peak Ratings of "Performance Improved" on the Visual Analog Scale', 'timeFrame': 'Subjects completed this measure at 15 minute intervals for 45 minutes after sampling each cocaine dose under both buspirone and placebo maintenance conditions.', 'description': 'Subjects rated their feelings of "Performance Improved" on a Visual Analog Scale. This item was rated from 0 (minimum)-100 (maximum) on a Visual Analog Scale. Higher values represent greater subjective effects on this item. Peak scores were calculated from multiple assessments for each cocaine dose under both buspirone and placebo conditions.'}, {'measure': 'Peak Ratings of "Restless" on the Visual Analog Scale', 'timeFrame': 'Subjects completed this measure at 15 minute intervals for 45 minutes after sampling each cocaine dose under both buspirone and placebo maintenance conditions.', 'description': 'Subjects rated their feelings of "Restless" on a Visual Analog Scale. This item was rated from 0 (minimum)-100 (maximum) on a Visual Analog Scale. Higher values represent greater subjective effects on this item. Peak scores were calculated from multiple assessments for each cocaine dose under both buspirone and placebo conditions.'}, {'measure': 'Peak Ratings of "Rush" on the Visual Analog Scale', 'timeFrame': 'Subjects completed this measure at 15 minute intervals for 45 minutes after sampling each cocaine dose under both buspirone and placebo maintenance conditions.', 'description': 'Subjects rated their feelings of "Rush" on a Visual Analog Scale. This item was rated from 0 (minimum)-100 (maximum) on a Visual Analog Scale. Higher values represent greater subjective effects on this item. Peak scores were calculated from multiple assessments for each cocaine dose under both buspirone and placebo conditions.'}, {'measure': 'Peak Ratings of "Shaky, Jittery" on the Visual Analog Scale', 'timeFrame': 'Subjects completed this measure at 15 minute intervals for 45 minutes after sampling each cocaine dose under both buspirone and placebo maintenance conditions.', 'description': 'Subjects rated their feelings of "Shaky, Jittery" on a Visual Analog Scale. This item was rated from 0 (minimum)-100 (maximum) on a Visual Analog Scale. Higher values represent greater subjective effects on this item. Peak scores were calculated from multiple assessments for each cocaine dose under both buspirone and placebo conditions.'}, {'measure': 'Peak Ratings of "Sluggish, Fatigued, Lazy" on the Visual Analog Scale', 'timeFrame': 'Subjects completed this measure at 15 minute intervals for 45 minutes after sampling each cocaine dose under both buspirone and placebo maintenance conditions.', 'description': 'Subjects rated their feelings of "Sluggish, Fatigued, Lazy" on a Visual Analog Scale. This item was rated from 0 (minimum)-100 (maximum) on a Visual Analog Scale. Higher values represent greater subjective effects on this item. Peak scores were calculated from multiple assessments for each cocaine dose under both buspirone and placebo conditions.'}, {'measure': 'Peak Ratings of "Stimulated" on the Visual Analog Scale', 'timeFrame': 'Subjects completed this measure at 15 minute intervals for 45 minutes after sampling each cocaine dose under both buspirone and placebo maintenance conditions.', 'description': 'Subjects rated their feelings of "Stimulated" on a Visual Analog Scale. This item was rated from 0 (minimum)-100 (maximum) on a Visual Analog Scale. Higher values represent greater subjective effects on this item. Peak scores were calculated from multiple assessments for each cocaine dose under both buspirone and placebo conditions.'}, {'measure': 'Peak Ratings of "Willing to Take Again" on the Visual Analog Scale', 'timeFrame': 'Subjects completed this measure at 15 minute intervals for 45 minutes after sampling each cocaine dose under both buspirone and placebo maintenance conditions.', 'description': 'Subjects rated their feelings of "Willing to Take Again" on a Visual Analog Scale. This item was rated from 0 (minimum)-100 (maximum) on a Visual Analog Scale. Higher values represent greater subjective effects on this item. Peak scores were calculated from multiple assessments for each cocaine dose under both buspirone and placebo conditions.'}, {'measure': 'Peak Ratings of "Talkative, Friendly" on the Visual Analog Scale', 'timeFrame': 'Subjects completed this measure at 15 minute intervals for 45 minutes after sampling each cocaine dose under both buspirone and placebo maintenance conditions.', 'description': 'Subjects rated their feelings of "Talkative, Friendly" on a Visual Analog Scale. This item was rated from 0 (minimum)-100 (maximum) on a Visual Analog Scale. Higher values represent greater subjective effects on this item. Peak scores were calculated from multiple assessments for each cocaine dose under both buspirone and placebo conditions.'}, {'measure': 'Peak Oral Temperature', 'timeFrame': 'This measure was completed at 15 minute intervals for 45 minutes after sampling each cocaine dose under both buspirone and placebo maintenance conditions.', 'description': 'Oral temperature was measured with an automated monitor. Higher values represent greater temperature. Peak scores were calculated from multiple assessments for each cocaine dose under both buspirone and placebo conditions.'}, {'measure': 'Peak Diastolic Blood Pressure', 'timeFrame': 'This measure was completed at 15 minute intervals for 45 minutes after sampling each cocaine dose under both buspirone and placebo maintenance conditions.', 'description': 'Diastolic blood pressure was measured with an automated monitor. Higher values represent greater diastolic pressure. Peak scores were calculated from multiple assessments for each cocaine dose under both buspirone and placebo conditions.'}, {'measure': 'Peak Heart Rate', 'timeFrame': 'This measure was completed at 15 minute intervals for 45 minutes after sampling each cocaine dose under both buspirone and placebo maintenance conditions.', 'description': 'Heart rate was measured with an automated monitor. Higher values represent greater heart rate. Peak scores were calculated from multiple assessments for each cocaine dose under both buspirone and placebo conditions.'}]}, 'oversightModule': {'oversightHasDmc': False}, 'conditionsModule': {'conditions': ['Cocaine Use Disorders']}, 'referencesModule': {'references': [{'pmid': '20638380', 'type': 'BACKGROUND', 'citation': 'Stoops WW, Lile JA, Glaser PE, Hays LR, Rush CR. Intranasal cocaine functions as reinforcer on a progressive ratio schedule in humans. Eur J Pharmacol. 2010 Oct 10;644(1-3):101-5. doi: 10.1016/j.ejphar.2010.06.055. Epub 2010 Jul 16.'}]}, 'descriptionModule': {'briefSummary': 'Cocaine use disorders are an unrelenting public health concern. Intensive research efforts have yielded behavioral interventions that reduce cocaine use, however, these interventions are not universally effective and treatment effects diminish over time. Development of a pharmacotherapy that enhances the efficacy of these interventions is a priority for the National Institute on Drug Abuse. This study proposes to determine the impact of buspirone maintenance on self-administration of cocaine and alternative reinforcers. These preliminary data will be used to support further research developing buspirone as a pharmacotherapy for cocaine use disorders. We hypothesize that buspirone will attenuate the reinforcing effects of cocaine and increase the reinforcing effects of alternative reinforcers.'}, 'eligibilityModule': {'sex': 'ALL', 'stdAges': ['ADULT'], 'maximumAge': '55 Years', 'minimumAge': '18 Years', 'healthyVolunteers': True, 'eligibilityCriteria': 'Inclusion Criteria:\n\n* Recent cocaine use\n\nExclusion Criteria:\n\n* Abnormal screening outcome (e.g., ECG, blood chemistry result) that study physicians deem clinically significant\n* Current or past histories of substance abuse or dependence that are deemed by the study physicians to interfere with study completion\n* History of serious physical disease, current physical disease, impaired cardiovascular functioning, chronic obstructive pulmonary disease, history of seizure or current or past histories of serious psychiatric disorder that in the opinion of the study physician would interfere with study participation will be excluded from participation\n* Females not currently using effective birth control\n* Contraindications to cocaine or buspirone'}, 'identificationModule': {'nctId': 'NCT01639157', 'briefTitle': 'Impact of Buspirone Maintenance on the Reinforcing Effects of Cocaine', 'organization': {'class': 'OTHER', 'fullName': 'University of Kentucky'}, 'officialTitle': 'Human Laboratory Study of the Impact of Buspirone Maintenance on the Reinforcing, Subjective and Performance Effects of Cocaine', 'orgStudyIdInfo': {'id': 'R21DA034095-01', 'link': 'https://reporter.nih.gov/quickSearch/R21DA034095-01', 'type': 'NIH'}}, 'armsInterventionsModule': {'armGroups': [{'type': 'EXPERIMENTAL', 'label': 'Buspirone', 'description': 'Subjects will be maintained on 30 mg buspirone daily.', 'interventionNames': ['Drug: Buspirone']}, {'type': 'PLACEBO_COMPARATOR', 'label': 'Placebo', 'description': 'Subjects will be maintained on placebo (i.e., 0 mg buspirone daily).', 'interventionNames': ['Drug: Placebo']}], 'interventions': [{'name': 'Buspirone', 'type': 'DRUG', 'description': 'Subjects will be maintained on oral buspirone (10 mg administered 3 times daily) for 6 days each during the study in random order.', 'armGroupLabels': ['Buspirone']}, {'name': 'Placebo', 'type': 'DRUG', 'description': 'Subjects will be maintained on oral placebo (0 mg administered 3 times daily) for 6 days each during the study in random order.', 'armGroupLabels': ['Placebo']}]}, 'contactsLocationsModule': {'locations': [{'zip': '40536', 'city': 'Lexington', 'state': 'Kentucky', 'country': 'United States', 'facility': 'University of Kentucky Medical Center', 'geoPoint': {'lat': 37.98869, 'lon': -84.47772}}], 'overallOfficials': [{'name': 'William W Stoops, Ph.D.', 'role': 'PRINCIPAL_INVESTIGATOR', 'affiliation': 'University of Kentucky'}]}, 'sponsorCollaboratorsModule': {'leadSponsor': {'name': 'William Stoops', 'class': 'OTHER'}, 'collaborators': [{'name': 'National Institute on Drug Abuse (NIDA)', 'class': 'NIH'}], 'responsibleParty': {'type': 'SPONSOR_INVESTIGATOR', 'investigatorTitle': 'Assistant Professor', 'investigatorFullName': 'William Stoops', 'investigatorAffiliation': 'University of Kentucky'}}}}